CPH signs deal to import and distribute its first human cannabinoid product into Australia
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Creso Pharma Limited (ASX:CPH) today announced it had secured an important deal with its Australian distribution partner, Health House International, for the import and distribution of its first cannabinoid-based human health product.
cannaQIX®50, the company’s proprietary buccally formulated cannabidiol (CBD) lozenge product for chronic pain is due to be imported by Health House International in CY2018.
CPH has done a deal for the import and distribution of cannaQIX®50.
The agreement stipulates that Health House will import and distribute the product under local medicinal cannabis regulations. CPH is in the process of working with Australian State and Federal Government and health authorities.
The deal is a key part pf CPH’s overall corporate strategy to expand its international distribution channels, particularly in the Australian market. In addition, it adds to the company’s competitive edge in the Australian market — following its achievement of being the first Australian company to import medicinal cannabis into Australia in May of this year.
It should be noted, however, that CPH is in the early stages of its market penetration and investors should seek professional financial advice if considering this stock for their portfolio.
Once cannaQIX®50 is imported, Health House will distribute to pharmacies in all Australian states and territories. The lozenges will be available through the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS). The TGA administers the SAS which provides a pathway allowing eligible medical practitioners to apply for approval to prescribe medicinal cannabis products. As a prescription CBD product, physicians outside of Queensland and Tasmania only need to apply to the TGA for approval and not their respective state health authorities.
Each lozenge will contain 50mg of CBD from full hemp plant extracts along with niacin, vitamins B6, B12, C and zinc in a proprietary standardised pharma-grade formulation produced in Switzerland.
The unique advantages of cannaQIX®50
What makes the cannaQIX®50 lozenges ideal is not just the ingredients but the delivery formulation, which is designed for buccal absorption and for dissolving in the mouth. This method is more efficient than tablets or capsules, which need to be swallowed and therefore can have a higher chance of active ingredients being lost when passing through the intestine and liver.
Through absorption in the mouth, cannaQIX®50’s active ingredients enter the blood stream directly, avoiding this first pass through the liver.
In commenting on today’s announcement, Creso Pharma CEO and Co‐Founder, Dr. Miri Halperin Wernli said: “We are thrilled to be introducing our first Creso innovative human health product into Australia in CY2018 and are pleased to be one of the first companies to provide medicinal cannabis products to approved patients here.
“There is a considerable unmet patient need for innovative and more patient-friendly CBD products in Australia and our cannaQIX®50 product will provide patients with a pharmaceutical-grade, process-certified and proprietary standardised formulation product.
“The move also cements our position in the Australian market and enhances our competitive position after being the first Australian company to import medicinal cannabis into Australia earlier this year.”
Health House International Director, Paul Mavor added: “An estimated 1 in 5 Australian adults suffer from chronic pain at huge costs to the healthcare system, their quality of life and their family and friends. Products like cannaQIX®50 are a game changer for Creso and Health House International.
“Its pharmaceutically sophisticated dosage form meets a current unmet need in CBD products and I believe it will be very successful with prescribers, patients and pharmacists alike because it doesn’t require the need to calculate non-standardised drops for oil-based CBD products.”
CPH is in advanced discussions regarding distribution agreements for further cannaQIX® products, including to countries such as Switzerland, Germany, UK, Italy, Spain, Netherlands, Belgium, Sweden, as well as in Canada and Latin America.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
